Association of osteoprotegerin with peripheral artery disease in patients with type 2 diabetes

Archives of Cardiovascular Diseases

Volumn 108, Issue 8-9, 2015, Pages 412-419

  Esteghamati, Alireza ^a   Aflatoonian, Maryam ^a   Rad, Mona Vahidi ^a   Mazaheri, Tina ^a   Mousavizadeh, Mostafa ^a   Nakhjavani, Manouchehr ^a   Noshad, Sina ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ankle brachial index; Osteoprotegerin; Peripheral vascular diseases diagnosis; Severity of Illness Index; Type 2 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; OSTEOPROTEGERIN; BIOLOGICAL MARKER; TNFRSF11B PROTEIN, HUMAN;

ADULT; AGE; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BLOOD VESSEL OCCLUSION; BODY MASS; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIABETIC FOOT; DISEASE SEVERITY; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LEG; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; SEX; SMOKING; BLOOD; CHI SQUARE DISTRIBUTION; COLOR DOPPLER FLOWMETRY; COMPLICATION; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; UPREGULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; BIOMARKERS; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OSTEOPROTEGERIN; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; ULTRASONOGRAPHY, DOPPLER, COLOR; UP-REGULATION;

EID: 84941739438     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2015.01.015     Document Type: Article

References (35)

1. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Inter-mittent claudication. A risk profile from The Framingham HeartStudy. Circulation 1997;96:44-9.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for periph-eral arterial disease in the United States: results from theNational Health and Nutrition Examination Survey, 1999-2000.Circulation 2004;110:738-43.
3. Criqui MH, Langer RD, Fronek A, et al. Mortality over a periodof 10 years in patients with peripheral arterial disease. N EnglJ Med 1992;326:381-6.
4. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease,diabetes, and reduced lower extremity functioning. DiabetesCare 2002;25:113-20.
5. Marso SP, Hiatt WR. Peripheral arterial disease in patients withdiabetes. J Am Coll Cardiol 2006;47:921-9.
6. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, HolmanRR. UKPDS 59: hyperglycemia and other potentially modifiablerisk factors for peripheral vascular disease in type 2 diabetes.Diabetes Care 2002;25:894-9.
7. Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterialdisease in diabetic and nondiabetic patients: a comparison ofseverity and outcome. Diabetes Care 2001;24:1433-7.
8. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteo-protegerin: paracrine regulators of bone metabolism and vas-cular function. Arterioscler Thromb Vasc Biol 2002;22:549-53.
9. Dhore CR, Cleutjens JP, Lutgens E, et al. Differential expressionof bone matrix regulatory proteins in human atheroscleroticplaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003.
10. Bucay N, Sarosi I, Dunstan CR, et al. osteoprotegerin-deficientmice develop early onset osteoporosis and arterial calcifica-tion. Genes Dev 1998;12:1260-8.
11. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels areassociated with the presence and severity of coronary arterydisease. Circulation 2002;106:1192-4.
12. Ren MY, Sui SJ, Zhang Y, et al. Increased plasma osteoprotegerinlevels are associated with the presence and severity of acutecoronary syndrome. Acta Cardiol 2008;63:615-22.
13. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasmaconcentrations correlate with severity of peripheral artery dis-ease. Atherosclerosis 2005;182:175-80.
14. Browner WS, Lui LY, Cummings SR. Associations of serumosteoprotegerin levels with diabetes, stroke, bone density,fractures, and mortality in elderly women. J Clin EndocrinolMetab 2001;86:631-7.
15. Esteghamati A, Arefzadeh A, Zandieh A, Salehi Sadaghiani M, Noshad S, Nakhjavani M. Comparison of osteoprotegerinand vascular endothelial growth factor in normoalbuminurictype 1 diabetic and control subjects. J Endocrinol Invest2013;36:474-7.
16. Knudsen ST, Foss CH, Poulsen PL, Andersen NH, Mogensen CE, Rasmussen LM. Increased plasma concentrations of osteo-protegerin in type 2 diabetic patients with microvascularcomplications. Eur J Endocrinol 2003;149:39-42.
17. Olesen P, Ledet T, Rasmussen LM. Arterial osteoprotegerin:increased amounts in diabetes and modifiable synthesis fromvascular smooth muscle cells by insulin and TNF-alpha. Dia-betologia 2005;48:561-8.
18. American Diabetes A. Diagnosis and classification of diabetesmellitus. Diabetes Care 2013;36(Suppl. 1):S67-74.
19. Ranke C, Creutzig A, Alexander K. Duplex scanning of theperipheral arteries: correlation of the peak velocity ratiowith angiographic diameter reduction. Ultrasound Med Biol1992;18:433-40.
20. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is arisk factor for progressive atherosclerosis and cardiovasculardisease. Circulation 2004;109:2175-80.
21. Anand DV, Lahiri A, Lim E, Hopkins D, Corder R. The relationshipbetween plasma osteoprotegerin levels and coronary arterycalcification in uncomplicated type 2 diabetic subjects. J AmColl Cardiol 2006;47:1850-7.
22. Ali Z, Ellington AA, Mosley Jr TH, Kullo IJ. Association of serumosteoprotegerin with ankle-brachial index and urine albumin:creatinine ratio in African-Americans and non-Hispanic whites.Atherosclerosis 2009;206:575-80.
23. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules andatherosclerosis. Atherosclerosis 2003;170:191-203.
24. Mangan SH, Van Campenhout A, Rush C, Golledge J. Osteo-protegerin upregulates endothelial cell adhesion moleculeresponse to tumor necrosis factor-alpha associated with induc-tion of angiopoietin-2. Cardiovasc Res 2007;76:494-505.
25. Schoppet M, Al-Fakhri N, Franke FE, et al. Localization of osteo-protegerin, tumor necrosis factor-related apoptosis-inducingligand, and receptor activator of nuclear factor-kappaB ligandin Monckeberg's sclerosis and atherosclerosis. J Clin EndocrinolMetab 2004;89:4104-12.
26. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novelaspects on RANK ligand and osteoprotegerin in osteoporosis andvascular disease. Calcif Tissue Int 2004;74:103-6.
27. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reversesosteoporosis by inhibiting endosteal osteoclasts and preventsvascular calcification by blocking a process resembling osteo-clastogenesis. J Exp Med 2000;192:463-74.
28. Secchiero P, Corallini F, Pandolfi A, et al. An increased osteopro-tegerin serum release characterizes the early onset of diabetesmellitus and may contribute to endothelial cell dysfunction.Am J Pathol 2006;169:2236-44.
29. Xiang GD, Xu L, Zhao LS, Yue L, Hou J. The relationship betweenplasma osteoprotegerin and endothelium-dependent arterialdilation in type 2 diabetes. Diabetes 2006;55:2126-31.
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared withconventional treatment and risk of complications in patientswith type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
31. American Diabetes A. Peripheral arterial disease in people withdiabetes. Diabetes Care 2003;26:3333-41.
32. Bernstein EF, Fronek A. Current status of noninvasive tests inthe diagnosis of peripheral arterial disease. Surg Clin North Am1982;62:473-87.
33. Jager KA, Phillips DJ, Martin RL, et al. Noninvasive map-ping of lower limb arterial lesions. Ultrasound Med Biol1985;11:515-21.
34. Kohler TR, Nance DR, Cramer MM, Vandenburghe N, Strand-ness Jr DE. Duplex scanning for diagnosis of aortoiliac andfemoropopliteal disease: a prospective study. Circulation1987;76:1074-80.
35. Polak JF, Karmel MI, Mannick JA, O'Leary DH, Donald-son MC, Whittemore AD. Determination of the extent oflower-extremity peripheral arterial disease with color-assistedduplex sonography: comparison with angiography. AJR Am JRoentgenol 1990;155:1085-9.